Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.
A large, detailed look by Kaiser Permanente researchers at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority for receiving the medication.
A follow-up program for Kaiser Permanente Northern California patients discharged from the hospital was associated with reduced readmissions without increased mortality, new research in the journal BMJ suggests.
New study describes how patients and physicians benefitted when Kaiser Permanente Northern California established a virtual, multidisciplinary gastric cancer team.
Health systems could use data from routine clinical care to identify the onset of upcoming COVID-19 surges as many as 6 weeks before they occur, Kaiser Permanente researchers found in a study published in the journal BMJ Open.
A Kaiser Permanente genetic analysis found 82 locations on the human genome associated with migraine, 48 of them newly identified, including 3 specific to women, who experience migraine much more frequently than men.
Kaiser Permanente study found Black patients as well as patients who had obesity, liver disease, or sepsis or other signs of infection were among those more likely to be at high risk for a blood clot.
Kaiser Permanente study suggests the increased incidence of chilblains — or, COVID toes — seen during pandemic was related to behavior changes, not the coronavirus.
Using data from Kaiser Permanente and United Kingdom biobanks, researchers have identified new locations on the human genome that could relate to the risk of age-related cataract.
About 75 children are scheduled to receive their first vaccination against COVID-19 as part of the Pfizer/BioNTech vaccine clinical trial through Kaiser Permanente Northern California.